(Q46735730)

24 December 2017

title

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma (English)

1 reference

24 December 2017

main subject

phase I clinical trial

0 references

0 references

1

Paul Richardson

1 reference

24 December 2017

Kenneth C. Anderson

13

Kenneth Anderson

1 reference

24 December 2017

Constantine S Mitsiades

2

Constantine Mitsiades

1 reference

24 December 2017

Kathleen Colson

3

Kathleen Colson

1 reference

24 December 2017

Laura McBride

5

Laura McBride

1 reference

24 December 2017

author name string

Eileen Reilly

4

1 reference

24 December 2017

Judy Chiao

6

1 reference

24 December 2017

Linda Sun

7

1 reference

24 December 2017

Justin Ricker

8

1 reference

24 December 2017

Syed Rizvi

9

1 reference

24 December 2017

Carol Oerth

10

1 reference

24 December 2017

Barbara Atkins

11

1 reference

24 December 2017

Ivy Fearen

12

1 reference

24 December 2017

David Siegel

14

1 reference

24 December 2017

publication date

1 March 2008

1 reference

24 December 2017

published in

Leukemia & Lymphoma

1 reference

24 December 2017

volume

49

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

502-507

1 reference

24 December 2017

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Emerging drugs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701817258

10.1080/10428190701817258

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017